Spatial Patterns of Hypometabolism and Amyloid Deposition in Variants of Alzheimer’s Disease Corresponding to Brain Networks: a Prospective Cohort Study
- 116 Downloads
To identify the most vulnerable network among typical and three variants of Alzheimer’s disease (AD) and to link amyloid-β (Aβ) deposition and downstream network dysfunction.
In this study, 38 typical AD, 11 frontal variants, 8 logopenic variants, 6 posterior variants, and 20 normal controls were enrolled. 2-(4′-[11C] Methylaminophenyl)-6-hydroxybenzothiazole ([11C]PIB) and 2-deoxy-2-fluoro-d-glucose ([18F]FDG) positron emission tomography (PET) imaging were performed. Voxel-wise statistical analysis was used for [18F]FDG analysis, whereas two-sample t test was performed between each AD group and control group. Moreover, the goodness of fit (GOF) of t-maps with brain functional network templates was assessed, and the most vulnerable network in each phenotypic of AD was chosen as volume of interests (VOIs). [11C]PIB binding potential (BPND) of VOIs were generated by using PMOD software. In addition, statistical analysis of BPND among four types of AD in each specific network was calculated by SPSS software.
The hypometabolism patterns indicated that in typical and frontal variants of AD, the most vulnerable network was the left executive control network (GOF score = 4.3, 5.0). For the logopenic variant, the highest GOF score (1.9) belonged to the auditory network. For the posterior variant, the higher visual network was the most vulnerable (GOF score = 6.0). The [11C]PIB BPND showed that there were no significant differences (p > 0.05) among AD groups within the specific networks.
The phenotypic diversity of AD correlates with specific functional network failure; however, Aβ plaques do not associate with specific network vulnerability.
Key wordsAlzheimer’s disease Amyloid-β [18F]FDG [11C]PIB Positron-emission tomography
The study was supported by the National Natural Science Foundation of China (Grant NO. 81571057 and 81501035), Tianjin Science and Technology Project (Grant NO. 16ZXMJSY00010).
Compliance with Ethical Standards
This study was approved by the Ethics Committee of Tianjin Medical University General Hospital (IRB2014–071-01).
Conflict of Interest Statement
The authors declare that they have no conflict of interest.
- 5.Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K, DeKosky ST, Gauthier S, Selkoe D, Bateman R, Cappa S, Crutch S, Engelborghs S, Frisoni GB, Fox NC, Galasko D, Habert MO, Jicha GA, Nordberg A, Pasquier F, Rabinovici G, Robert P, Rowe C, Salloway S, Sarazin M, Epelbaum S, de Souza LC, Vellas B, Visser PJ, Schneider L, Stern Y, Scheltens P, Cummings JL (2014) Advancing research diagnostic criteria for Alzheimer’s disease: the IWG-2 criteria. Lancet Neurol 13:614–629CrossRefGoogle Scholar
- 6.Lehmann M, Ghosh PM, Madison C, Laforce R Jr, Corbetta-Rastelli C, Weiner MW, Greicius MD, Seeley WW, Gorno-Tempini ML, Rosen HJ, Miller BL, Jagust WJ, Rabinovici GD (2013) Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer’s disease. Brain 136:844–858CrossRefGoogle Scholar
- 11.Buckner RL, Sepulcre J, Talukdar T et al (2009) Cortical hubs revealed by intrinsic functional connectivity: mapping, assessment of stability and relation to Alzheimer’s disease. Neurobiol Dis 29:1860–1873Google Scholar
- 18.Matías-Guiu JA, Cabrera-Martín MN, Pérez-Castejón MJ, Moreno-Ramos T, Rodríguez-Rey C, García-Ramos R, Ortega-Candil A, Fernandez-Matarrubia M, Oreja-Guevara C, Matías-Guiu J, Carreras JL (2015) Visual and statistical analysis of 18F-FDG PET in primary progressive aphasia. Eur J Nucl Med Mol Imaging 42:916–927CrossRefGoogle Scholar
- 21.Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N, Mormino EC, O'Neil JP, Janabi M, Karydas A, Growdon ME, Jang JY, Huang EJ, DeArmond SJ, Trojanowski JQ, Grinberg LT, Gorno-Tempini ML, Seeley WW, Miller BL, Jagust WJ (2011) Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 77:2034–2042CrossRefGoogle Scholar
- 27.Rosenbloom MH, Alkalay A, Agarwal N, Baker SL, O'Neil JP, Janabi M, Yen IV, Growdon M, Jang J, Madison C, Mormino EC, Rosen HJ, Gorno-Tempini ML, Weiner MW, Miller BL, Jagust WJ, Rabinovici GD (2011) Distinct clinical and metabolic deficits in PCA and AD are not related to amyloid distribution. Neurology 76:1789–1796CrossRefGoogle Scholar
- 32.Dronse J, Fliessbach K, Bischof GN, von Reutern B, Faber J, Hammes J, Kuhnert G, Neumaier B, Onur OA, Kukolja J, van Eimeren T, Jessen F, Fink GR, Klockgether T, Drzezga A (2017) In vivo patterns of tau pathology, amyloid-β burden, and neuronal dysfunction in clinical variants of Alzheimer’s disease. J Alzheimers Dis 55:465–471CrossRefGoogle Scholar
- 33.Gutierrez A, Vitorica J (2018) Toward a new concept of Alzheimer’s disease models: a perspective from neuroinflammation. J Alzheimers Dis:1–10Google Scholar
- 34.Yamane T, Ishii K, Sakata M et al (2017) Inter-rater variability of visual interpretation and comparison with quantitative evaluation of 11C-PiB PET amyloid images of the Japanese Alzheimer’s Disease Neuroimaging Initiative (J-ADNI) multicenter study. Eur J Nucl Med Mol Imaging 44:850–857CrossRefGoogle Scholar